Beraprost

Beraprost

Systematic (IUPAC) name
2,3,3a,8b-tetrahydro-2-hydroxy-1-(3-hydroxy-4- methyl-1-octen-6-ynyl)-1H-cyclopenta(b)benzofuran- 5-butanoic acid
Clinical data
AHFS/Drugs.com	International Drug Names
Legal status	?
Routes of administration	Oral
Pharmacokinetic data
Bioavailability	50–70%
Metabolism	Unknown
Biological half-life	35–40 minutes
Excretion	?
Identifiers
CAS Number	88430-50-6 Y Template:CAS
ATC code	B01AC19 (WHO)
PubChem	CID: 5282428
IUPHAR/BPS	1967
ChemSpider	5293169 Y
UNII	35E3NJJ4O6 Y
ChEMBL	CHEMBL1207745 N
Chemical data
Formula	C24H30O5
Molecular mass	398.492 g/mol
InChI InChI=1S/C24H30O5/c1-3-4-7-15(2)19(25)13-12-17-20(26)14-21-23(17)18-10-5-8-16(24(18)29-21)9-6-11-22(27)28/h5,8,10,12-13,15,17,19-21,23,25-26H,6-7,9,11,14H2,1-2H3,(H,27,28)/b13-12+/t15?,17-,19+,20+,21-,23-/m0/s1 Y Key:CTPOHARTNNSRSR-APJZLKAGSA-N Y
NY (what is this?)  (verify)

Beraprost is a synthetic analogue of prostacyclin, under clinical trial for the treatment of pulmonary hypertension. It is also being studied for use in avoiding reperfusion injury.

Clinical pharmacology

As an analogue of prostacyclin PGI₂, beraprost affects vasodilation, which in turn lowers blood pressure. Beraprost also inhibits platelet aggregation, though the role this phenomenon may play in relation to pulmonary hypertension has yet to be determined.

Dosage and administration

Beraprost is administered orally as a pill available in strength of 20 mcg. Dose ranges from 60 to 180 mcg in divided doses after meals.